Oncolytics Biotech is conducting clinical trials in multiple indications with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program comprises human trials using REOLYSIN® both alone and in combination with chemotherapy, radiotherapy and/or a checkpoint inhibitor, delivered via local and/or intravenous administration.

Trial Number Phase Trial Name Indication Location Status
REO 019
Phase Ib Intravenous Administration of REOLYSIN® in Combination with Bortezomib (VELCADE®) and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Multiple Myeloma US
US
Ongoing
REO 024
Phase Ib Intravenous Administration of REOLYSIN® in Combination with Pembrolizumab (KEYTRUDA®) and Chemotherapy in Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Pancreatic Cancer US
US
Ongoing
MC-1472
Phase I Intravenous Administration of REOLYSIN® in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumours Brain Cancer US
US
Ongoing
NCI-9603
Translational Intravenous Administration of REOLYSIN® in Combination with Dexamethasone and Carfilzomib for Patients with Relapsed or Refractory Myeloma Multiple Myeloma US
US
Ongoing
IND 213
Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel for Patients with Advanced or Metastatic Breast Cancer Breast Cancer Canada
Canada
Ongoing
IND 211
Phase II Intravenous Administration of REOLYSIN® in Combination with Docetaxel or Pemetrexed for Patients with Previously-Treated Advanced or Metastatic Non-Small Cell Lung Cancer Lung Cancer Canada
Canada
Ongoing
IND 210
Phase II Intravenous Administration of REOLYSIN® in Combination with FOLFOX-6 and Bevacizumab (Avastin®) in Patients with Advanced or Metastatic Colorectal Cancer Colorectal Cancer Canada
Canada
Ongoing
IND 209
Phase II Intravenous Administration of REOLYSIN® in Combination with Docetaxel for Patients with Recurrent or Metastatic Castration Resistant Prostate Cancer Prostate Cancer Canada
Canada
Ongoing
NCI-9030
Phase I Intravenous Administration of REOLYSIN® Monotherapy for Patients with Relapsed or Refractory Multiple Myeloma Multiple Myeloma US
US
Complete
NCI-8601
Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Metastatic Pancreatic Cancer Pancreatic Cancer US
US
Ongoing
COG-ADVL1014
Phase I Intravenous Administration of REOLYSIN® in Combination with Cyclophosphamide for Pediatric Patients with Relapsed or Refractory Solid Tumours Advanced Malignancies US
US
Complete
GOG-0186H
Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel for Patients with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Ovarian, Fallopian Tube and Primary Peritoneal Cancers US
US
Ongoing
REO 022
Phase I Intravenous Administration of REOLYSIN® in Combination with FOLFIRI and Bevacizumab (Avastin®) in FOLFIRI-Naïve Patients with Mutant Metastatic Colorectal Cancer Colorectal Cancer US
US
Ongoing
REO 021
Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin in Patients with Squamous Cell Carcinoma of the Lung Lung Cancer US
US
Complete
REO 020
Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Metastatic Melanoma Melanoma US
US
Complete
REO 018
Phase III Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Platinum-Refractory, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Head and Neck Cancer International
International
Complete
REO 017
Phase II Intravenous Administration of REOLYSIN® in Combination with Gemcitabine (Gemzar®) for Patients with Advanced or Metastatic Pancreatic Cancer Pancreatic Cancer US
US
Complete
REO 016
Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer with KRAS- or EGFR-Activated Tumours Lung Cancer US
US
Complete
REO 015
Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Advanced or Metastatic, Platinum-Refractory Head and Neck Cancers Head and Neck Cancer US
US
Complete
REO 014
Phase II Intravenous Administration of REOLYSIN® Monotherapy for Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung Advanced Malignancies US
US
Complete
REO 013 Brain
Translational Brain: Intravenous Administration of REOLYSIN® Monotherapy in Patients Prior to Surgical Resection of Recurrent High Grade Primary or Metastatic Brain Tumours Brain Cancer UK
UK
Ongoing
NCI-7848
Phase II Intravenous Administration of REOLYSIN® Monotherapy for Patients with Metastatic Melanoma Melanoma US
US
Complete
REO 013
Translational Intravenous Administration of REOLYSIN® Monotherapy for Patients with Metastatic Colorectal Cancer Colorectal Cancer UK
UK
Complete
NCI-7853
Phase I Systemic and Intraperitoneal Administration of REOLYSIN® Monotherapy for Patients with Platinum-Refractory, Metastatic Ovarian Epithelial, Peritoneal and Fallopian Tube Cancers Ovarian, Fallopian Tube and Primary Peritoneal Cancers US
US
Complete
REO 012
Phase I Intravenous Administration of REOLYSIN® in Combination with Cyclophosphamide for Patients with Advanced or Metastatic Solid Tumours Advanced Malignancies UK
UK
Complete
REO 011
Phase I/II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Patients with Platinum-Refractory, Advanced, Recurrent or Metastatic Head and Neck Cancers Head and Neck Cancer UK
UK
Complete
REO 010
Phase I Intravenous Administration of REOLYSIN® in Combination with Docetaxel for Patients with Advanced or Metastatic Solid Tumours Advanced Malignancies UK
UK
Complete
REO 009
Phase I Intravenous Administration of REOLYSIN® in Combination with Gemcitabine (Gemzar®) for Patients with Advanced or Metastatic Solid Tumours Advanced Malignancies UK
UK
Complete
REO 008
Phase II Intratumoural Administration of REOLYSIN® in Combination with Low-Dose Radiation in Patients with Advanced Malignancies Advanced Malignancies UK
UK
Complete
REO 007
Phase I Infusion of REOLYSIN® Monotherapy for Patients with Recurrent Malignant Gliomas Brain Cancer US
US
Complete
REO 006
Phase I Local Administration of REOLYSIN® in Combination with Radiation for Patients with Advanced Malignancies Advanced Malignancies UK
UK
Complete
REO 005
Phase I Intravenous Administration of REOLYSIN® Monotherapy for Patients with Various Advanced Stage Tumours Advanced Malignancies UK
UK
Complete
REO 004
Phase I Intravenous Administration of REOLYSIN® Monotherapy for Patients with Various Advanced or Metastatic Solid Tumours Advanced Malignancies US
US
Complete
REO 003
Phase I/II Intratumoural Administration of REOLYSIN® Monotherapy for Patients with Recurrent Malignant Gliomas Brain Cancer Canada
Canada
Complete
REO 002
Translational Intratumoural Administration of REOLYSIN® Monotherapy for Patients with T2 Prostate Cancer Prostate Cancer Canada
Canada
Complete
REO 001
Phase I Intratumoural Administration of REOLYSIN® Monotherapy for Patients with Advanced Subcutaneous Tumours Advanced Malignancies Canada
Canada
Complete

REOLYSIN® is currently available in a clinical trial setting only. It has not been approved in any jurisdiction and is not available for purchase. The Company, its directors, officers, employees and affiliates have no influence over the inclusion of a patient in a clinical trial. Should a patient’s physician determine that he or she may be a suitable clinical trial candidate, they must contact a participating center. Contact information, as well as inclusion and exclusion criteria, for both US and international participating centers can be found at www.clinicaltrials.gov for studies with a US component.